Neoadjuvant therapy (NAT) administered before definitive surgery is a standard treatment option in patients with BC, especially in aggressive subtypes, such as triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) positive breast cancer [2,4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.